Amneal Pharmaceuticals FY Conference Summary Company Overview - **Company**: Amneal Pharmaceuticals (NasdaqGS:AMRX) - **Fiscal Year**: 2025 results discussed, with guidance for 2026 provided - **Key Executives**: Chirag Patel (Co-CEO), Joseph Todisco (Finance), Anthony DiMeo (Investor Relations) Key Points from the Conference 1. Fiscal Year 2025 Performance - 2025 was described as an "amazing year" with raised guidance for future performance [5][7] - The Affordable Medicines Group, which includes generics, injectables, and biosimilars, has grown 5% over the last five years and is expected to grow in high single digits moving forward [7][8] 2. Business Segments - **Affordable Medicines Group**: - Comprises generics, injectables, and biosimilars [7] - Generics segment is strong, with 92% of prescriptions filled using generics [21] - New product launches in ophthalmics and transdermal patches are expected to drive growth [23][24] - **Specialty Segment**: - Despite loss of exclusivity (LOE) for Rytary, the specialty segment is expected to remain steady [99] - Crexont has shown remarkable performance, converting 80% of ER patients in its first year [58][66] - **AvKARE**: - Focused on the VA/DoD channel, which is the most profitable [12] - De-emphasizing low-margin distribution business, which generated approximately $350 million in top line but minimal profit [12][13] 3. Product Highlights - **Crexont**: - Expected to generate $300 million to $500 million in revenue, with potential for more than doubling from $63 million in the current year [66][68] - Designed to improve patient adherence and outcomes compared to Rytary [70] - **Brekiya**: - Targeting cluster headache patients with an auto-injector, projected peak sales of $50 million to $100 million [79][81] - **Biosimilars**: - Upcoming launches include denosumab and Xolair, with significant growth anticipated in 2026 and beyond [31][35] - A pipeline of 110 products, with 27 potential launches planned [40] 4. Strategic Initiatives - Focus on vertical integration for biosimilars and enhancing manufacturing capabilities [120] - Partnership with Pfizer through the Metsera deal, allowing access to 18 countries and exclusive rights for certain products [110][112] 5. Financial Outlook - Guidance for 2026 indicates 7%-8% growth, with potential for higher growth if biosimilars are successfully executed [43][47] - Expected margin improvement of 100 basis points in 2026 due to enhanced manufacturing and distribution capabilities [56] 6. Market Position and Future Growth - Amneal aims to become a top five player in the biosimilars market in the U.S. [124] - Continued investment in R&D, with a budget of $180 million to $200 million [120] - Growth opportunities in international markets, particularly in India and through partnerships in Europe [125] 7. Awards and Recognition - Amneal was awarded "Best Company to Work For" by BioSpace, marking a significant achievement for an affordable medicines company [8] Conclusion - Amneal Pharmaceuticals is positioned for continued growth with a strong focus on innovation, product launches, and strategic partnerships. The company is optimistic about its future in the biosimilars market and aims to enhance its profitability through targeted investments and operational efficiencies.

Financial Data and Key Metrics Changes - In Q4 2025, total company revenues grew 11% to a record $814 million, with adjusted EBITDA increasing by 13% and adjusted EPS rising by 75% [18][19] - For the full year 2025, total company revenue reached $3 billion, an 8% increase, with adjusted EBITDA growing 10% to $688 million and adjusted EPS rising 43% to $0.83 [21][20] - Operating cash flow for the full year was strong at $340 million, and net leverage was reduced to 3.5 times [18][21] Business Line Data and Key Metrics Changes - The affordable medicines segment was flat at $437 million in Q4, while specialty revenues surged 38% year-over-year to $167 million, driven by strong demand for key brands [19][20] - AvKARE revenues grew 24% to $211 million, benefiting from strong growth in the government channel [19] - For the full year, affordable medicines grew 4%, specialty grew 19%, and AvKARE grew 12% [21] Market Data and Key Metrics Changes - The specialty segment's growth was attributed to products like CREXONT, Rytary, and the new Brekiya auto-injector [19] - The company expects to launch 20-30 new products each year in the affordable medicines segment, with a focus on complex generics and injectables [11][12] Company Strategy and Development Direction - The company aims to become America's number one affordable medicines company, focusing on innovative therapies and expanding access to complex medicines [6][5] - A strategic focus on vertical integration in biosimilars is emphasized, with plans to build a strong commercial platform and manufacturing capabilities [7][14] - The company is also enhancing operational efficiency through digitization, automation, and AI [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing a strong foundation and multiple growth drivers, including new branded launches and a robust pipeline of affordable medicines [29][28] - The company anticipates continued growth in 2026, with guidance for revenue growth of 1%-4%, adjusted EBITDA growth of 5%-10%, and adjusted EPS growth of 12%-24% [22][23] Other Important Information - The company was recently added to the S&P SmallCap 600 index, enhancing visibility with the investment community [27] - The company is well-positioned to capitalize on the upcoming wave of biologics losing exclusivity, which presents significant long-term growth opportunities [8][14] Q&A Session Summary Question: Update on CREXONT market response and revenue targets for 2026 - Management reported a significant uptake with 80% of IR patients converting to CREXONT, aiming to double market share and reach 100,000 patients in 2026 [33][34] Question: Clarification on AvKARE's growth expectations - Management explained that while the distribution business is declining, the government channel remains strong, and gross margins have improved significantly [39][40] Question: Status of the Pfizer GLP-1 partnership - The collaboration is progressing well, with no immediate changes expected, and the company retains marketing rights for several countries [49][48] Question: Insights on the generic Omnipaque opportunity - Management acknowledged the complexity of the supply chain but expressed optimism about market entry and growth potential [58][60] Question: Discussion on Xolair and market competition - Management highlighted the limited competition expected in the Xolair market and the potential for significant revenue contributions starting in 2027 [59][60]

Financial Data and Key Metrics Changes - Revenue grew 8% in 2025, reaching $3 billion, with adjusted EBITDA increasing by 10% to $688 million and adjusted EPS rising by 43% to $0.83 [4][21][22] - Q4 revenues increased by 11% to a record $814 million, with adjusted EBITDA growing 13% and adjusted EPS soaring 75% [19][20] Business Segment Data and Key Metrics Changes - Affordable Medicines segment revenue was flat at $437 million, while Specialty revenues surged 38% to $167 million, driven by strong demand for key brands [20] - AvKARE revenues grew 24% to $211 million, benefiting from strong growth in the government channel [20] Market Data and Key Metrics Changes - The specialty segment, particularly CREXONT, achieved a market share of over 3% one year post-launch, with expectations to double revenue in 2026 [9][35] - The company anticipates a significant opportunity in biosimilars, with plans to have six products in the U.S. market by 2027 [6][14] Company Strategy and Development Direction - The company aims to become America's number one affordable medicines company, focusing on innovative therapies and expanding access to complex medicines [5] - Strategic growth opportunities include expanding the injectable segment and building a strong commercial platform for biosimilars [6][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing a strong foundation and a robust pipeline of new product launches [4][30] - The company expects continued top and bottom line growth in 2026, with guidance indicating revenue growth of 1%-4% and adjusted EBITDA growth of 5%-10% [24][25] Other Important Information - The company successfully reduced net leverage from 7.4x in 2019 to 3.5x at the end of 2025, and refinanced its debt to lower interest expenses [22][23] - Amneal was added to the S&P SmallCap 600 index, enhancing visibility with the investment community [29] Q&A Session Summary Question: Update on CREXONT market response and revenue targets - Management noted a significant uptake with 80% of IR patients converting to CREXONT, aiming to double market share and reach 100,000 patients in 2026 [35][36] Question: Growth expectations for AvKARE - Management explained that while the distribution business is declining, the government channel remains strong, with gross margins improving significantly [40][41] Question: Status of the Pfizer GLP-1 partnership - The collaboration is progressing well, with no immediate changes expected, and the company retains marketing rights for 18 countries [49] Question: Generic Omnipaque opportunity and competition - Management acknowledged the complexity of the supply chain but expressed confidence in capturing market share, with plans to introduce additional strengths [56][59] Question: Xolair market potential - Management highlighted the limited competition in the Xolair market and expected strong sales through private label partnerships [58][59]

Core Insights - Amneal Pharmaceuticals is transitioning from a traditional retail generics model to focus on complex dosage forms and specialty products, with a significant emphasis on the U.S. market, which accounts for approximately 98% of its revenue [2][3] Financial Performance - The company has doubled its revenue and EBITDA over the past six years, reducing net leverage from 7.4 to 3.7, and expects EBITDA to grow faster than revenue in 2026, with projected gross margin improvement of 50–60 basis points and double-digit EPS growth [4][6][8] Product Strategy - Amneal is shifting towards higher-value "affordable medicines," including complex generics, injectables, biosimilars, and branded neurology, while reducing its reliance on standard oral solids, which now represent about 25% of revenue [1][5][12] - The company has launched three biosimilars and is preparing to launch two denosumab presentations, aiming to become a top-three player in the biosimilars market [14][15] Crexont Performance - Crexont, Amneal's Parkinson's therapy, reached approximately 22,000 patients in its first year, achieving a 3.2% market share, with expectations to double sales to over $120 million this year and target a 5%–6% market share by 2026 [5][9][10] R&D and Future Growth - R&D investment is expected to remain around $180 million, with a focus on generating additional Phase 4 data to support product performance and market uptake [7][11] - The company is also pursuing vertical integration in manufacturing, particularly for biosimilars, with a target completion by 2026 [15][16] Market Dynamics - The competitive landscape for retail generics has intensified since 2017–2018 due to increased FDA approvals and buyer concentration, prompting Amneal to adapt its strategy [1][2] - The company anticipates typical annual price erosion of 4%–5% as a stable headwind, but expects to mitigate this through product mix and operational efficiencies [7]

Amneal Pharmaceuticals FY Conference Summary Company Overview - **Company**: Amneal Pharmaceuticals (NasdaqGS:AMRX) - **Date**: December 03, 2025 - **Context**: Discussion at the 37th Annual Piper Sandler Healthcare Conference Key Points Industry and Business Evolution - Amneal has undergone a significant financial turnaround over the past six years, diversifying its business and reducing debt, leading to its best operational state in years [2][4] - The company has shifted focus from oral solid generics to more complex generics, injectables, and biosimilars, which are less exposed to price erosion [3][4] Affordable Medicines Segment - The affordable medicines business generates approximately $1.5 billion in revenue, growing at mid- to high-single digits [3] - Oral solids revenue contribution has decreased from 53% to about 25% over the past few years, with expectations to drop to 10%-15% in the future [3][4] - 65% of ANDAs pending at the FDA are in complex generics, with 90% of the R&D pipeline focused on this area [4] Generic Injectables - Annual revenue from generic injectables has grown from $130 million to an expected $200 million this year, with projections of $240-$250 million next year [7] - The company has about 40 products in the generic injectables space and plans to add approximately 10 new products annually [7] - Notable upcoming product launches include Risperidone, IXO, and Lanreotide [7] Biosimilars - Amneal has transitioned into biosimilars, generating about $100 million in revenue this year with three products launched [11] - The company anticipates launching five new biosimilars by 2028, with a significant opportunity in the generic Xolair market, valued at $4 billion and growing at 30% annually [12][14] - The company expects to be the second generic in the market for Xolair, which could yield hundreds of millions in revenue [16] Specialty Products - Crexont, a new product for Parkinson's patients, is expected to generate $60 million in revenue this year, with projections of $120 million next year [23][24] - The product is priced between $3,000 and $5,000 annually, significantly lower than competitors like AbbVie's Vyalev [28][29] - The company is conducting a phase four study to demonstrate Crexont's effectiveness, with results expected to enhance its market position [25] Partnerships and Future Outlook - Amneal has partnered with Pfizer regarding the Metsera pipeline, with plans to build two new manufacturing sites in India [36][37] - The company is exploring opportunities in the GLP-1 market, focusing on complex peptides and manufacturing capabilities for future generics [42] Financial Metrics - The overall gross margin for Amneal is approximately 44%, with injectables achieving around 50% margins and potential for biosimilars like Xolair to reach 80% [20][22] - Current EBITDA stands at about 22%, with potential to exceed 30% if the company captures full margins from its products [22] Additional Insights - The company emphasizes organic growth and selective M&A, with a focus on building a sustainable business model over the next 10-20 years [19] - Amneal's strategy includes minimizing exposure to price erosion by focusing on less competitive segments of the market [4][5]

Financial Data and Key Metrics Changes - In Q1 2025, total revenues reached $695 million, reflecting a 5% growth year-over-year [4][28] - Adjusted EBITDA for the quarter was $170 million, which is a 12% increase compared to the previous year [4][30] - Adjusted EPS grew by 50%, reaching $0.21, driven by higher adjusted EBITDA and lower interest expenses [30] Business Line Data and Key Metrics Changes - Affordable Medicines segment generated $415 million in revenue, up 6%, with new product launches contributing $41 million [29] - Specialty segment revenue was $108 million, a 3% increase, primarily driven by the performance of Crexon and Unitroid [29] - AvKARE revenues were $172 million, growing 6%, with strong growth in the government channel [29] Market Data and Key Metrics Changes - The specialty segment's market share for Crexon has surpassed 1% and is projected to exceed 3% by the end of the year [7] - Trexon has achieved approximately 60% coverage of US lives, doubling from 30% in February [8] - The healthcare segment is expected to reach over $900 million in revenue by 2027 [15] Company Strategy and Development Direction - The company aims to be a leader in affordable medicines, focusing on innovation, quality, and operational excellence [5][16] - Amneal is expanding its specialty branded portfolio and anticipates launching a DHE auto injector later this year [9][21] - The strategic partnership with MedCera in the GLP-1 space is expected to drive long-term growth through new manufacturing facilities [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving peak sales of $300 to $500 million for Trexon and highlighted the strong market uptake of Crexon [9][27] - The company is well-positioned to address drug shortages and enhance patient access through its robust manufacturing capabilities [18][19] - Management affirmed full-year 2025 expectations, projecting total net revenue between $3 billion and $3.1 billion, reflecting 7% to 11% growth [33] Other Important Information - The company has a diverse array of growth drivers, including biosimilars, injectables, and specialty products [15][26] - Amneal has filed regulatory applications for five additional biosimilars this year, with a goal of having six biosimilars on the market by 2027 [14][25] Q&A Session Summary Question: What is the expected top-line contribution from biosimilars? - Management expects a total contribution of around $105 to $160 million from biosimilars, with Alimpsus projected to contribute between $90 to $100 million [40][41] Question: When will vertical integration for biosimilars occur? - Vertical integration is expected to be executed by the end of this year or early next year, with a focus on establishing a significant presence in the biosimilars market [41][42] Question: What is the focus between complex products and drug shortages in injectables? - The company is focusing equally on both complex products and addressing drug shortages, with a robust pipeline of injectable products [45][46]

Financial Data and Key Metrics Changes - In Q4 2024, revenues reached $731 million, growing 18% year-over-year, with adjusted EBITDA of $155 million, reflecting a 9% increase [42][45][49] - For the full year 2024, total revenues were $2.8 billion, a 17% increase from the previous year, and adjusted EBITDA was $627 million, up 12% [47][49] - Net leverage decreased to 3.9 times, down from 4.8 times at the end of 2023, and significantly reduced from 7.4 times at the end of 2019 [40][49] Business Line Data and Key Metrics Changes - The affordable medicine segment grew 21% in Q4 to $439 million, with full-year growth of 15% [42][47] - Specialty revenues increased 16% in Q4 to $121 million, driven by branded products, including $3 million from the newly launched Crexent [44][47] - The RevCare segment saw a 14% growth in Q4 to $170 million, with expectations for continued double-digit growth [22][45] Market Data and Key Metrics Changes - The specialty business is projected to grow to over $500 million by 2027, driven by Crexent and other branded products [10] - The global biosimilar market is expected to grow from $33 billion today to $75 billion by 2030, with significant opportunities due to expiring patents [18][19] Company Strategy and Development Direction - The company aims to enhance its long-term growth profile through strategic initiatives, including the launch of Crexent and expansion into the biosimilars market [8][11] - A collaboration with Medcera in the weight loss and obesity space is expected to drive innovation and growth, with plans to commercialize products in 20 emerging markets [12][13] - The company is focused on becoming vertically integrated in biosimilars and expanding its injectable portfolio [37][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving continued top and bottom-line growth in 2025, despite the anticipated loss of exclusivity for Rytary [41][50] - The company is optimistic about the early success of Crexent and its potential to become a leading therapy for Parkinson's disease [44][68] - Management highlighted the importance of maintaining a strong cash flow and reducing debt while investing in growth areas [52][54] Other Important Information - The company fulfilled over 162 million prescriptions annually in the U.S. and is the largest U.S. manufacturer of affordable medicines [24] - The company is targeting to become a top player in the U.S. injectables and biosimilars markets in the coming years [24] Q&A Session Summary Question: Can you elaborate on the launch of Crexent? - Management reported strong early adoption and positive patient testimonials, with formulary access currently at about 30% and expected to rise to 50% [60][65] Question: What are the expectations for GLP-1 launches by 2028? - Management indicated that the launches could include products like Trulicity and involve contract manufacturing, with a manageable CapEx of $100 to $150 million over three years [80] Question: Any updates on naloxone contracts? - Management noted that progress is being made with several states, aiming to provide about 2.5 million kits this year, increasing to 4 million by 2026 [92] Question: What is the long-term opportunity for Unithroid? - Management sees consistent growth potential for Unithroid, similar to Synthroid, as it provides stable therapy for patients [94] Question: What is the target for debt reduction in 2025? - Management aims to reduce net debt to EBITDA to around 3.6% to 3.7% in 2025, with a gross debt reduction target of $80 to $100 million [95][96]

Financial Data and Key Metrics Changes - In Q4 2024, revenues reached $731 million, an 18% increase year-over-year, with double-digit growth across all segments [42][46] - For the full year 2024, total revenues were $2.8 billion, a $400 million or 17% increase compared to the previous year, exceeding guidance [47][49] - Adjusted EBITDA for 2024 was $627 million, growing 12% year-over-year, and operating cash flow was $348 million [48][49] - Net leverage decreased to 3.9 times, down from 4.8 times at the end of 2023, achieving the target a year ahead of schedule [40][49] Business Line Data and Key Metrics Changes - The affordable medicine segment generated $1.7 billion in 2024, growing 15%, driven by new launches and a diversified portfolio [14][47] - Specialty business grew 14% in 2024, with a goal to exceed $500 million by 2027, supported by products like Crexent and Unithroid [10][11] - RevCare segment revenue grew 25% to $900 million, with expectations for continued double-digit growth [22][49] Market Data and Key Metrics Changes - The biosimilars segment generated $126 million in revenue in 2024, with plans for six commercial biosimilars by 2027 [17][18] - The global biosimilar market is projected to grow from $33 billion to $75 billion by 2030, presenting significant opportunities for the company [18][19] Company Strategy and Development Direction - The company aims to enhance its long-term growth profile through strategic initiatives like the launch of Crexent and collaboration with Medcera in the weight loss space [8][11] - Plans to build two new high-volume peptide manufacturing facilities to support the Medcera collaboration and expand capabilities in the weight loss market [12][30] - The focus remains on vertical integration and expanding the biosimilars portfolio, with a commitment to R&D and operational excellence [20][37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving continued top and bottom-line growth in 2025, despite the anticipated loss of exclusivity for Rytary [41][50] - The company is optimistic about the early success of Crexent and its potential to become a leading therapy for Parkinson's disease [10][44] - Management highlighted the importance of maintaining a strong organic pipeline while considering strategic M&A opportunities [72][86] Other Important Information - The company is positioned as the largest US manufacturer of affordable medicines, fulfilling over 162 million prescriptions annually [24] - The strategic focus includes expanding into emerging markets and enhancing global access for products like Crexent [68] Q&A Session Summary Question: Can you elaborate on the launch of Crexent? - Management reported strong early adoption and positive patient testimonials, with formulary access currently at about 30% and expected to increase [60][65] Question: What are the thoughts on organic investments versus external business development? - The company is focused on a solid organic pipeline while also looking for strategic acquisitions to enhance its portfolio [72][86] Question: Any updates on naloxone contracts and Unithroid's long-term opportunity? - Naloxone contracts are progressing slowly, with expectations to provide 2.5 million kits this year [92] - Unithroid is expected to maintain a consistent growth profile similar to Synthroid [94] Question: What is the target for debt reduction in 2025? - The company aims to reduce net debt to EBITDA to around 3.6% to 3.7% in 2025, with a gross debt reduction target of $80 to $100 million [95][96]